A presentation by BerGenBio and Oncoinvent will be held as a webcast in English on Wednesday 2 July 2025 at 10:00am CEST including a Q&A session. A company presentation of Oncoinvent in in Norwegian will follow at 11:00am CEST. To join the webcast please sign up via https://channel.royalcast.com/landingpage/hegnarmedia/20250702_1/ for English, and https://channel.royalcast.com/landingpage/hegnarmedia/20250702_2/ for Norwegian
Bergen, Norway and Oslo, Norway, 30 June 2025: BerGenBio ASA the (“Company”) hereby announces a fully underwritten rights issue with preferential subscription rights (the “Subscription Rights”) for the Company’s existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the “Merger”) to raise gross proceeds of approximately NOK 130 million, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters comprising certain large shareholders in Oncoinvent ASA and certain external underwriters (the “Underwriters”) (the “Rights Issue”). The Rights Issue is subject to and will be completed subsequent to the completion of the Merger. The Merger is currently anticipated to be completed mid of September 2025 and the Rights Issue will then be implemented start/mid of October 2025.
Bergen, Norway and Oslo, Norway, 30 June 2025 – BerGenBio ASA (OSE: BGBIO) (“BerGenBio” or the “Company”) and Oncoinvent ASA (OSE: ONCIN) (“Oncoinvent”) announce that they have entered into a merger agreement (the “Agreement”) to combine the two companies through a statutory merger (the “Merger”), where BerGenBio will be the acquiring entity.
Oncoinvent ASA (OSE: ONCIN) a clinical stage radiopharmaceutical company developing innovative treatments for solid cancers, invites for a presentation of the top-line results from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer. To join the webcast please click the link
Oncoinvent ASA (OSE: ONCIN) a clinical stage radiopharmaceutical company developing innovative treatments for solid cancers, invites for a presentation of the top-line results from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer.
Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent’s novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer
Oslo, 14 May 2025: The annual general meeting of Oncoinvent ASA was held today, on 14 May 2025, as a digital meeting through Microsoft Teams. All proposals on the agenda were adopted in accordance with the board of directors’ proposals and the proposals from the nomination committee.
The minutes of the annual general meeting are attached hereto and are also available on the company’s website www.oncoinvent.com/investors/general-meetings.
Oncoinvent ASA has today published the annual report for 2024. The annual report is attached and is also available on the Company’s website, www.oncoinvent.com.
A live streamed of company update in English. The live webcast will be available for everyone to join and there will be a Q&A sesion at the end of the company update. Please join by using the follwoing link (Teams): Oncoinvent ASA: Company update Q1 – 2025
In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a
Live streamed of quarterly presentation in English on Wednesday 30th of April at 11.00 AM CEST. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.
Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.